» Articles » PMID: 27154512

Molecular Cytogenetic Analysis of JAZF1, PHF1, and YWHAE in Endometrial Stromal Tumors: Discovery of Genetic Complexity by Fluorescence in Situ Hybridization

Overview
Journal J Mol Diagn
Publisher Elsevier
Date 2016 May 8
PMID 27154512
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Diagnosis of endometrial stromal tumors (ESTs) can be challenging, particularly endometrial stromal sarcomas (ESSs) because of variable histologic appearance, long latency to recurrence, frequent metastases with unknown primary, and overlap with endometrial stromal nodules and undifferentiated uterine sarcomas. To enhance EST diagnosis, a break-apart strategy fluorescence in situ hybridization panel to detect JAZF1, PHF1, and YWHAE rearrangements was applied to a cohort of primary or metastatic endometrial stromal nodules, ESSs, or undifferentiated uterine sarcomas (36 cases for JAZF1, 24 of which were also assessed for PHF1 and YWHAE), 24 myometrium/endometrium controls, and 37 non-ESTs in the differential diagnosis. JAZF1 was the most frequently altered gene and occurred in all EST types, JAZF1 and/or PHF1 were mutually exclusive from YWHAE involvement, and uterine and extrauterine ESTs have a shared pathogenesis. We further defined frequency of these rearrangements and provided a resource demonstrating the signal complexity that can manifest when evaluating JAZF1. Rearrangement of JAZF1 occurred in 47% of ESTs, most (70%) of which had atypical patterns representing multiple structural alterations and/or more than one clone. YWHAE and PHF1 rearrangements each occurred in 8% of ESTs. An exceptional case was an ESS without JAZF1 or MEAF6 disruption that further disputes correlation of PHF1 involvement with the sex cord-like variant. These results expand our understanding of the genetic heterogeneity that defines ESTs.

Citing Articles

Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature.

De Almeida B, Dos Anjos L, Dobroff A, Baracat E, Yang Q, Al-Hendy A Biomedicines. 2022; 10(10).

PMID: 36289829 PMC: 9599831. DOI: 10.3390/biomedicines10102567.


Genetic variation of gene-"Switch" of disease control.

Jin X, Dai M, Zhou Y Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(1):101-108.

PMID: 35545369 PMC: 10930477. DOI: 10.11817/j.issn.1672-7347.2022.210394.


TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition.

Chiang S, Vasudevaraja V, Serrano J, Stewart C, Oliva E, Momeni-Boroujeni A Mod Pathol. 2021; 35(1):117-127.

PMID: 34561551 PMC: 10317054. DOI: 10.1038/s41379-021-00922-7.


RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report.

Seryakov A, Magomedova Z, Suntsova M, Prokofieva A, Rabushko E, Glusker A Front Oncol. 2021; 11:666001.

PMID: 34527573 PMC: 8435728. DOI: 10.3389/fonc.2021.666001.


CT, MRI, and FDG-PET imaging findings of low-grade extrauterine endometrial stromal sarcoma arising from the mesentery: A case report.

Suzuki S, Kurokawa R, Tsuruga T, Mori-Uchino M, Nishida H, Kato T Radiol Case Rep. 2021; 16(9):2774-2779.

PMID: 34367393 PMC: 8326572. DOI: 10.1016/j.radcr.2021.06.063.